Clinical trial
Single-Dose Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets (30 mg; Mylan) and Sular® Extended Release Tablets (30 mg; First Horizon) in Healthy Volunteers
NCT00985660 is registered in ClinicalTrials.gov with Mylan Pharmaceuticals Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single-Dose Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets (30 mg; Mylan) and Sular® Extended Release Tablets (30 mg; First Horizon) in Healthy Volunteers
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2007
- Completion date
- July 31, 2007
- Enrollment
- 78 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy